@article{e0e84158683a4ccd8f076d0d191e0687,
title = "Ticagrelor monotherapy in patients with diabetes mellitus undergoing percutaneous coronary interventions: Insights from the TWILIGHT trial",
keywords = "Diabetes, Percutaneous coronary intervention, TWILIGHT, Ticagrelor",
author = "Angiolillo, {Dominick J.} and Usman Baber and Roxana Mehran",
note = "Funding Information: Conflict of interest: D.J.A. reports receiving grant support, consulting fees, and honoraria from Abbott, Amgen, Aralez, Bayer, Biosensors, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Daiichi Sankyo, Eli Lilly, Janssen, Merck, and Sanofi, consulting fees and honoraria from Haemonetics, PhaseBio, PLx Pharma, Pfizer, and the Medicines Company, grant support and fees for review activities from CeloNova, fees for review activities from St. Jude Medical, and grant support from CSL Behring, Eisai, Gilead, Idorsia Pharmaceuticals, Matsutani Chemical Industry, Novartis, Osprey Medical, RenalGuard Solutions, and the Scott R. MacKenzie Foundation. U.B. reports honoraria from Boston Scientific,",
year = "2021",
doi = "10.1093/CVR/CVAA120",
language = "English",
volume = "116",
pages = "E70--E72",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "7",
}